ESMO/LinkedIn
Mar 4, 2025, 07:35
DESTINY-Breast07 phase Ib/II trial presented at ESMO TAT 2025
ESMO posted on LinkedIn:
“Updated results presented at ESMO TAT 2025 from the DESTINY-Breast07 phase Ib/II trial showed encouraging confirmed overall response rates with trastuzumab deruxtecan (T-DXd) alone and T-DXd plus pertuzumab in untreated HER2-positive Advanced Breast Cancer. Safety data were consistent with their individual known profiles.
Giuseppe Curigliano comments on the findings and awaits data from the first-line DESTINY-Breast09 phase III trial comparing T-DXd alone or in combination with pertuzumab with standard care.
Check out the full article in the ESMO Daily Reporter.”
Further Reading: ESMO TAT 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 4, 2025, 07:35
Mar 4, 2025, 07:21
Mar 4, 2025, 07:15
Mar 4, 2025, 07:09
Mar 4, 2025, 07:09
Mar 4, 2025, 07:03
Mar 4, 2025, 06:56
Mar 4, 2025, 06:41
Mar 4, 2025, 06:37